Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 88, Issue 3, 2014, Pages 737-745

  Yang, Qiang ^a   Zhang, Ting ^a   Wang, Chunling ^a   Jiao, Jiao ^a   Li, Jing ^a   Deng, Yihui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cancer stem like cells; CD133+ cells; Coencapsulation; Epirubicin liposomes; Metformin; S180 cell

Indexed keywords

CD133 ANTIGEN; EDETIC ACID; EPIRUBICIN; LIPOSOME; METFORMIN; PEGYLATED LIPOSOME; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MACROGOL DERIVATIVE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CANCER SIZE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL SELECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DELAYED DRUG RELEASE; DRUG SENSITIVITY; ENCAPSULATION; FLOW CYTOMETRY; G0 PHASE CELL CYCLE CHECKPOINT; G1 PHASE CELL CYCLE CHECKPOINT; LIPOSOMAL DELIVERY; MAGNETIC ACTIVATED CELL SORTING; MALE; MEMBRANE PERMEABILITY; MOUSE; MTT ASSAY; NONHUMAN; PH; SARCOMA; SARCOMA CELL LINE; TEMPERATURE; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; DRUG FORMULATION; INBRED MOUSE STRAIN; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; SARCOMA 180; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG CARRIERS; DRUG COMPOUNDING; EPIRUBICIN; GLYCOPROTEINS; LIPOSOMES; MALE; METFORMIN; MICE, INBRED STRAINS; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PEPTIDES; POLYETHYLENE GLYCOLS; SARCOMA 180; SURFACE PROPERTIES;

EID: 84912567184     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.10.006     Document Type: Article

References (34)

1. J.M. Adams, and A. Strasser Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res. 68 2008 4018 4021
2. M.F. Clarke, J.E. Dick, P.B. Dirks, C.J. Eaves, C.H.M. Jamieson, D.L. Jones, J. Visvader, I.L. Weissman, and G.M. Wahl Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells Cancer Res. 66 2006 9339 9344
3. T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M.A. Caligiuri, and J.E. Dick A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 367 1994 645 648
4. M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke Prospective identification of tumorigenic breast cancer cells Proc. Natl. Acad. Sci. 100 2003 3983 3988
5. A. Eramo, F. Lotti, G. Sette, E. Pilozzi, M. Biffoni, A. Di Virgilio, C. Conticello, L. Ruco, C. Peschle, and R. De Maria Identification and expansion of the tumorigenic lung cancer stem cell population Cell Death Differ. 15 2007 504 514
6. T. Schatton, G.F. Murphy, N.Y. Frank, K. Yamaura, A.M. Waaga-Gasser, M. Gasser, Q. Zhan, S. Jordan, L.M. Duncan, C. Weishaupt, R.C. Fuhlbrigge, T.S. Kupper, M.H. Sayegh, and M.H. Frank Identification of cells initiating human melanomas Nature 451 2008 345 349
7. A.T. Collins, P.A. Berry, C. Hyde, M.J. Stower, and N.J. Maitland Prospective identification of tumorigenic prostate cancer stem cells Cancer Res. 65 2005 10946 10951
8. S. Zhang, C. Balch, M.W. Chan, H.-C. Lai, D. Matei, J.M. Schilder, P.S. Yan, T.H.-M. Huang, and K.P. Nephew Identification and characterization of ovarian cancer-initiating cells from primary human tumors Cancer Res. 68 2008 4311 4320
9. L. Ricci-Vitiani, D.G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle, and R. De Maria Identification and expansion of human colon-cancer-initiating cells Nature 445 2007 111 115
10. S.K. Singh, C. Hawkins, I.D. Clarke, J.A. Squire, J. Bayani, T. Hide, R.M. Henkelman, M.D. Cusimano, and P.B. Dirks Identification of human brain tumour initiating cells Nature 432 2004 396 401
11. C. Li, D.G. Heidt, P. Dalerba, C.F. Burant, L. Zhang, V. Adsay, M. Wicha, M.F. Clarke, and D.M. Simeone Identification of pancreatic cancer stem cells Cancer Res. 67 2007 1030 1037
12. M. Baker Cancer stem cells tracked Nature 488 2012 13 14
13. R. Dowling, P. Goodwin, and V. Stambolic Understanding the benefit of metformin use in cancer treatment BMC Med. 9 2011 33
14. H.A. Hirsch, D. Iliopoulos, P.N. Tsichlis, and K. Struhl Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res. 69 2009 7507 7511
15. B. Bao, Z. Wang, S. Ali, A. Ahmad, A.S. Azmi, S.H. Sarkar, S. Banerjee, D. Kong, Y. Li, and S. Thakur Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells Cancer Prevent. Res. 5 2012 355 364
16. S. Del Barco, A. Vazquez-Martin, S. Cufí, C. Oliveras-Ferraros, J. Bosch-Barrera, J. Joven, B. Martin-Castillo, and J.A. Menendez Metformin: multi-faceted protection against cancer Oncotarget 2 2011 896
17. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discovery 4 2005 145 160
18. A.L. Klibanov, K. Maruyama, V.P. Torchilin, and L. Huang Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett. 268 1990 235 237
19. D. Papahadjopoulos, T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S.K. Huang, K.D. Lee, M.C. Woodle, D.D. Lasic, and C. Redemann Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. 88 1991 11460 11464
20. M. Kazuo Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects Adv. Drug Delivery Rev. 63 2011 161 169
21. A. Rahman, S.R. Husain, J. Siddiqui, M. Verma, M. Agresti, M. Center, A.R. Safa, and R.I. Glazer Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells J. Natl Cancer Inst. 84 1992 1909 1915
22. C. Mamot, D.C. Drummond, K. Hong, D.B. Kirpotin, and J.W. Park Liposome-based approaches to overcome anticancer drug resistance Drug Resist. Updates 6 2003 271 279
23. Y. Ma, Q. Yang, L. Wang, X. Zhou, Y. Zhao, and Y. Deng Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats Eur. J. Pharm. Sci. 45 2012 539 545
24. M.S. Wicha, S. Liu, and G. Dontu Cancer stem cells: an old idea - a paradigm shift Cancer Res. 66 2006 1883 1890
25. D. Mizrak, M. Brittan, and M.R. Alison CD133: molecule of the moment J. Pathol. 214 2008 3 9
26. G. Ferrandina, M. Petrillo, G. Bonanno, and G. Scambia Targeting CD133 antigen in cancer Expert Opin. Ther. Targets 13 2009 823 837
27. J. Neuzil, M. Stantic, R. Zobalova, J. Chladova, X. Wang, L. Prochazka, L. Dong, L. Andera, and S.J. Ralph Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name? Biochem. Biophys. Res. Commun. 355 2007 855 859
28. K.D. Collins, and M.W. Washabaugh The Hofmeister effect and the behaviour of water at interfaces Q. Rev. Biophys. 18 1985 323 422
29. L. Epameinondas Hofmeister anion effects on surfactant self-assembly and the formation of mesoporous solids Curr. Opin. Colloid Interface Sci. 7 2002 81 91
30. B. Ejlertsen, H.T. Mouridsen, S.T. Langkjer, J. Andersen, J. Sjöström, and M. Kjaer Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian breast group trial (SBG9403) J. Clin. Oncol. 22 2004 2313 2320
31. M. Jalving, J.A. Gietema, J.D. Lefrandt, S.d. Jong, A.K.L. Reyners, R.O.B. Gans, and E.G.E.d. Vries Metformin: taking away the candy for cancer? Eur. J. Cancer (Oxford, England: 1990) 46 2010 2369 2380
32. S. Del Barco, A. Vazquez-Martin, S. Cufi, C. Oliveras-Ferraros, J. Bosch-Barrera, J. Joven, B. Martin-Castillo, and J.A. Menendez Metformin: multi-faceted protection against cancer Oncotarget 2 2011 896 917
33. I.N. Alimova, B. Liu, Z. Fan, S.M. Edgerton, T. Dillon, S.E. Lind, and A.D. Thor Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro Cell Cycle 8 2009 909 915
34. B. Martin-Castillo, J. Dorca, A. Vazquez-Martin, C. Oliveras-Ferraros, E. Lopez-Bonet, M. Garcia, S. del Barco, and J.A. Menendez Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology Ann. Oncol. 21 2010 187 189